



2021/3/23

Company:	CYBERDYNE Inc.
Name of Representative:	Yoshiyuki Sankai, President and CEO
Code:	7779 (Mothers Section of the Tokyo Stock Exchange)
Contact:	Shinji Uga, Director and CFO (Tel. +81-29-869-9981)

【News】 Capital and Business Alliance with Jiksak Bioengineering

CYBERDYNE Inc. [Tsukuba, Ibaraki, CEO: Yoshiyuki Sankai from now on referred to as the "Company")] and Jiksak Bioengineering, Inc. (Kawasaki, Kanagawa, Japan, CEO: Jiro Kawada, from now on referred to as "Jiksak"), a company that develops neuron related technologies, announced to form a capital and business alliance (CYBERDYNE's investment in Jiksak). Furthermore, the Cybernetics Excellence Japan Fund 1 Investment Limited Partnership (CEJ Fund), operated by CEJ Capital Inc., will also invest in Jiksak.

Jiksak specializes in developing unique technologies to treat Amyotrophic Lateral Sclerosis (ALS) using iPS cell-derived nerve cells called Nerve Organoids. Nerve Organoids are for analyzing nerve tissue and inducing synapses. The Company will fuse its experience gathered through Cybernetics Treatment with Wearable Cyborg HAL to ALS drug discovery and regenerative medicine, which Jiksak is promoting. The two companies will further accelerate the development of new treatments for neuromuscular diseases.

(Comment by President Sankai)

Jiksak is a biotechnology company led by passionate challengers who are deepening and evolving advanced technologies around neurons. In addition to its achievements related to axons in neural tissue, Jiksak is now adding the latest technological achievements related to synaptic connections that can contribute to the development of ALS treatments and other neurological intractable diseases. We expect Jiksak to play an essential role in the related industry in the years to come. With the addition of Cybernetics Technology, a discontinuous evolution will begin. We look forward to walking with Jiksak.

Jiksak Bioengineering, Inc. : <https://www.jiksak.co.jp>